ノルフロキサシン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H319：強い眼刺激

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

  P337+P313：眼の刺激が続く場合：医師の診断/手当てを受けること。

ノルフロキサシン 価格

MSDS Information

• N-Desmethylpefloxacin

ノルフロキサシン 化学特性,用途語,生産方法

• 外観

  白色〜わずかにうすい黄色, 結晶性粉末〜粉末

• 溶解性

  酢酸に易溶、クロロホルム,エタノール,アセトン,水,酢酸エチルに難溶、エーテルに不溶。水酸化ナトリウム溶液に溶ける。

• 解説

  ノルフロキサシン，キノロン系抗菌薬．"白または薄黄色の結晶性粉末．融点220～221 ℃．UV(0.1 mol L－1 水酸化ナトリウム)λmax 274，325，336 nm(ε 35400，13900，13560)．pH 5以下または pH 10以上では水に易溶．最初のキノロン系抗菌剤であるナリジクス酸の類縁体として，シプロフロキサシンなどとともに開発された．細菌のトポイソメラーゼⅡであるDNAジャイレースを特異的に阻害する．抗菌スペクトルが広く，抗菌力が強い．ほかの抗生物質と耐性を示さない．臨床でよく使われる経口剤である．LD50 4 g/kg(マウス，経口)．

• 用途

  ノルフロキサシン定量用標準品。

• 用途

  グラム陰性桿菌とグラム陽性 球菌に対して抗菌作用を示します。

• 効能

  抗菌薬, 核酸合成阻害薬

• 商品名

  ノフロ (日医工); ノルフロキサシン (わかもと製薬); ノルフロキサシン (エルメッド); ノルフロキサシン (日医工ファーマ); ノルフロキサシン (日新製薬－山形); ノルフロキサシン (沢井製薬); ノルフロキサシン (陽進堂); ノルフロキサシン (鶴原製薬); バクシダール (杏林製薬); バクシダール (杏林製薬); バクシダール (杏林製薬); バスティーン (全星薬品工業); ビスコレット (富士薬品); マリオットン (鶴原製薬); ミタトニン (キョーリンリメディオ)

• 使用上の注意

  アルゴン封入

• 説明

  Norfloxacin is the first of the third generation nalidixic acid analogs to reach the marketplace. It exhibits potent in vitro and in vivo activity against Pseudomonas, enteric gram-negative rods and gram-positive cocci. Norfloxacin is orally effective in the treatment of urinary tract infections, including those due to organisms refractory to many other agents.

• 化学的特性

  Off-white to light yellow cryst powder

• 使用

  It finds it application as a fluorinated quinolone antibacterial. It is clinically used to treat urinary tract infections and prostatitis. In neutrophils from cirrhotic subjects, norfloxacin increases expression of IL-10 and heme oxygenase 1 (HO-1) and decreases expression of pro-inflammatory cytokines. Additionally, when complexed with gold(III), norfloxacin binds DNA and inhibits cellular proliferation in several cancer cell lines.

• 定義

  ChEBI: A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enz me called DNA gyrase.

• 抗菌性

  It is active against a wide range of Gram-negative bacteria, including Enterobacteriaceae and Campylobacter spp. Ps. aeruginosa, Acinetobacter, Serratia and Providencia spp. are weakly susceptible (and often resistant). It has no useful activity against anaerobes, Chlamydia, Mycoplasma and Mycobacterium spp.

• 応用例（製薬）

  A 6-fluoro, 7-piperazinyl quinoline available for oral administration and as an ophthalmic ointment.

• 薬物動態学

  Oral absorption: 50–70%
  C_max 400 mg oral :1.5 mg/L after 1–1.5 h
  Plasma half-life :3–4 h
  Volume of distribution: 2.5–3.1 L/kg
  Plasma protein binding: 15%
  absorption and distribution
  Norfloxacin displays linear kinetics. There is no significant accumulation with the recommended dosage of 400 mg every 12 h. Food slightly delays but does not otherwise impair absorption. Antacids reduce absorption. It is widely distributed, but concentrations in tissues other than those of the urinary tract are low： levels in the prostate are around 2.5 mg/g.
  Metabolism and excretion
  Six or more inactive metabolites are produced. Around 30% of a dose appears as unchanged drug in the urine and <10% as metabolites, producing peak concentrations of microbiologically active drug of around 100–400 mg/L. Urinary recovery is halved by probenecid, with little effect on the plasma concentration. The apparent plasma elimination half-life increases with renal impairment, rising to around 8 h in the anuric patient. Some of the drug appears in the bile where concentrations three- to seven-fold greater than the simultaneous plasma levels are achieved, but this is not a significant route of elimination and hepatic impairment is without effect. Very variable quantities, averaging 30% of a dose, appear in the feces, producing concentrations of active agent of around 200–2000 mg/kg.

• 臨床応用

  Complicated and uncomplicated urinary tract infections (including prophylaxis in recurrent infections), prostatitis
  Uncomplicated gonorrhea
  Gastroenteritis caused by Salmonella, Shigella and Campylobacter spp., Vibrio cholerae
  Conjunctivitis (ophthalmic preparation)

• 副作用

  Untoward reactions are those common to the fluoroquinolones. Gastrointestinal tract disturbances, which are generally mild, have been reported in 2–4% of patients. CNS disturbances have largely been limited to headache, drowsiness and dizziness. Co-administration with theophylline results in increased plasma theophylline levels.

• 安全性プロファイル

  Poison by intravenous route.Moderately toxic by other routes. Human systemic effectsby ingestion: musculoskeletal changes. An experimentalteratogen. Other experimental reproductive effects.Mutation data reported. When heated to decomposition itemits

ノルフロキサシン 上流と下流の製品情報

ノルフロキサシン 生産企業

Global(750)Suppliers

ノルフロキサシン スペクトルデータ(¹HNMR)

70458-96-7, ノルフロキサシン キーワード